Lundbeck and Merck sign exclusive commercialisation agreement for SYCREST (asenapine) sublingual tablets
Lundbeck expects to launch SYCREST in the EU at the beginning of 2011
H. Lundbeck A/S and Merck & Co., also known outside the United States and Canada as MSD, announced a commercialisation agreement for SYCREST® (asenapine) sublingual tablets (5 mg, 10 mg). Under the terms of the agreement, Lundbeck will pay an undisclosed fee as well as product supply payments in exchange for exclusive commercial rights to SYCREST® in all markets outside the United States, China and Japan. Lundbeck expects to launch SYCREST® in the European Union (EU), where it is already approved at the beginning of 2011. Merck will retain exclusive commercial rights to asenapine in the United States, China and Japan. Merck has launched asenapine in the United States under the brand name SAPHRIS® (asenapine) sublingual tablets (5 mg, 10 mg).
Other news from the department business & finance
